DOC

ANALYST NOTE: Healthpeak Properties, Inc. (DOC) Date: 2026-06-13 Current Price: $19.56

1. Structural Readiness

• State: Context-Only.
• Conservative Entry: —
• Breakout Level: —
• Extension: —
• ATR Current: 2.6% (Productive).

2. Thesis Layer

• Thesis Classification: TACTICAL / Setup-Led.
• Secular Thesis: None.

Analysis: There is no named secular thesis attached to DOC as of this date. The investment case is not driven by a specific macro narrative (e.g., "AI Infrastructure Boom" or "Demographic Silver Tsunami" as a primary driver) but is instead judged strictly on the quality of the business fundamentals and the readiness of the technical setup. As a tactical, setup-led name, conviction must be derived entirely from the operational evidence and the eventual formation of a structural entry point, rather than a pre-existing thematic tailwind.

3. Business Overview

Healthpeak Properties, Inc. operates as a fully integrated Real Estate Investment Trust (REIT) and an S&P 500 constituent. The company acquires, manages, and develops premier properties essential for medical research and healthcare services.

Portfolio Composition (as of March 31, 2026): The company holds interests in 688 properties across three core asset classes:

• Outpatient Medical: 504 properties. These are typically multi-tenant, with approximately 79% located on or adjacent to hospital campuses and 96% affiliated with hospital systems (as of Dec 31, 2025).
• Lab: 141 properties. Leased primarily to biotechnology, medical device, and pharmaceutical companies, as well as scientific research institutions.
• Senior Housing: 40 properties.
• Other: 3 properties.

Recent Operational Activity & Management Expectations:

• Leasing Momentum: Management expects to capture occupancy from new leasing commencements, projecting occupancy growth of at least 100 basis points versus year-end 2025. During the quarter ended March 31, 2026, the company executed nearly 1.1 million square feet of leases, including large renewals with partners such as Baylor Scott & White, Norton Health, and HCA.
• Capital Deployment & IPO: The company recently completed the IPO of its subsidiary, Janus Living, Inc., on March 23, 2026. The IPO generated $966 million in gross proceeds. Management stated that the IPO is expected to be earnings neutral to Healthpeak in 2026 but accretive in 2027 and beyond as capital deployment into acquisitions flows through.
• Acquisitions: In March 2026, Healthpeak acquired three portfolios of senior housing communities: two in Atlanta ($240M), three in Orlando ($121M), and one in Seattle ($41M).
• Financing: Concurrent with the Janus Living IPO, the company entered into a $400 million five-year unsecured term loan (maturing 2031) to support its capital structure.

4. Archetype and Conviction

• Archetype: Growth Leader.
• Valuation Context: The financial spine indicates a forward consensus EPS of $0.29875 for FY1 and $0.1375 for FY2.
• Conviction Stack:
• Thesis Strength: Low (No named secular thesis; purely tactical).
• Evidence Quality: High. The evidence base is robust, citing specific leasing volumes (1.1M sq ft), portfolio counts (688 properties), and precise capital deployment figures ($966M IPO proceeds, $502M in senior housing acquisitions).
• Structural Quality: Neutral. The business fundamentals are strong (diversified portfolio, strong tenant mix with hospital systems), but the technical structure is currently undefined.
• Rerating Potential: Dependent on the successful integration of the Janus Living IPO proceeds and the realization of the projected 100 bps occupancy growth.

The name fits the "Growth Leader" archetype based on its active acquisition strategy, successful spin-off/IPO execution, and management's guidance on occupancy expansion. However, without a defined structural setup, the conviction is limited to the fundamental strength of the business rather than a technical entry signal.

5. Invalidations, Strengths, and Gaps

• What Would Strengthen:
• Confirmation of the 100 basis point occupancy growth in the subsequent quarter.
• Successful deployment of the $966M IPO proceeds into high-yielding acquisitions that drive FFO per share growth.
• What Would Invalidate:
• A sustained decline in occupancy rates below year-end 2025 levels.
• Failure to deploy IPO capital efficiently, leading to earnings dilution rather than accretion in 2027.
• Gaps in Evidence:
• Specific Guidance on 2027 Accretion: While management expects accretion in 2027, the specific magnitude of this accretion is not quantified in the provided evidence.
• Capex Details: While acquisitions are noted, specific details on the cost of capital for the new term loan or the specific yield on the new acquisitions are not provided in the evidence block.

PRIVATE ANALYST CALL

Judgment: Hold Confidence: medium Key evidence: 1.1M sq ft of leases executed in Q1 2026 with major health system renewals; 2. Successful $966M Janus Living IPO completed March 2026; 3. Management guidance for 100 bps occupancy growth vs year-end 2025; 4. Diversified portfolio of 688 properties across outpatient, lab, and senior housing. Key risks: 1. No defined technical setup (Coil) exists to manage risk or define entry; 2. IPO proceeds may not be deployed efficiently to drive 2027 accretion; 3. Occupancy growth targets may not be met if leasing pipeline slows; 4. Interest rate sensitivity on the new $400M term loan. Expected path: Management expects to deploy IPO capital into acquisitions, driving occupancy growth and eventual earnings accretion in 2027. Expected horizon: 12-18 months for the thesis to play out via capital deployment and occupancy gains.